For instance, post-hoc analyses of pre- and post-treatment biopsy samples from Ewing sarcoma patients treated with either IGF-1R mAb or a combination of cixutumumab and the mTOR inhibitor temsirolimus revealed that median PFS and OS was better in phospho-IGF-1R-negative patients. This evidence concerns the gene IGF1R and Ewing sarcoma.